Coexisting Type 2 Inflammatory Conditions in Patients with Asthma Treated with Dupilumab: the RAPID Registry

Area of Science:

• Pulmonology
• Allergy and Immunology
• Dermatology
• Otolaryngology
• Gastroenterology

Background:

• Asthma frequently coexists with type 2 inflammatory diseases like allergic rhinitis, atopic dermatitis, and chronic rhinosinusitis.
• The RAPID registry (NCT04287621) was established to characterize real-world patients with asthma initiating dupilumab.
• This analysis specifically investigated the prevalence of these coexisting conditions.

Purpose of the Study:

• To determine the prevalence of coexisting type 2 inflammatory diseases in patients with asthma starting dupilumab treatment.
• To characterize the demographic and clinical features of these patients within a real-world setting.

Main Methods:

• The RAPID registry enrolled patients aged 12 years and older initiating dupilumab for asthma.
• Data were collected through regular assessments for up to 3 years, following standard care protocols.
• This analysis included 205 patients with available data at the time of evaluation.

Main Results:

• A high proportion of patients (92%) had at least one ongoing type 2 coexisting disease.
• The most common conditions were allergic rhinitis (80%), chronic rhinosinusitis with or without nasal polyposis (45%), and atopic dermatitis (27%).
• Patients initiating dupilumab were middle-aged, with a notable female predominance and long-standing asthma diagnoses.

Conclusions:

• Type 2 inflammatory diseases are highly prevalent in asthma patients initiating dupilumab in clinical practice.
• Accurate assessment of these coexisting conditions is crucial for optimizing patient care and management strategies.
• The findings underscore the systemic nature of type 2 inflammation in this patient population.